A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo

• Published in: Science translational medicine Vol. 16; no. 768; p. eado9026
• Main Authors: Misasi, John, Wei, Ronnie R, Wang, Lingshu, Pegu, Amarendra, Wei, Chih-Jen, Oloniniyi, Olamide K, Zhou, Tongqing, Moliva, Juan I, Zhao, Bingchun, Choe, Misook, Yang, Eun Sung, Zhang, Yi, Boruszczak, Marika, Chen, Man, Leung, Kwanyee, Li, Juan, Yang, Zhi-Yong, Andersen, Hanne, Carlton, Kevin, Godbole, Sucheta, Harris, Darcy R, Henry, Amy R, Ivleva, Vera B, Lei, Q Paula, Liu, Cuiping, Longobardi, Lindsay, Merriam, Jonah S, Nase, Danielle, Olia, Adam S, Pessaint, Laurent, Porto, Maciel, Shi, Wei, Wallace, Shannon M, Wolff, Jeremy J, Douek, Daniel C, Suthar, Mehul S, Gall, Jason G, Koup, Richard A, Kwong, Peter D, Mascola, John R, Nabel, Gary J, Sullivan, Nancy J
• Format: Journal Article
• Language: English
• Published: United States 09.10.2024
• Subjects: Animals; Antibodies, Bispecific - immunology; Antibodies, Bispecific - pharmacology; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - immunology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; Cricetinae; Epitopes - immunology; Humans; Immune Evasion; Mesocricetus; Mice; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - immunology
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.ado9026

Despite effective countermeasures, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persists worldwide because of its ability to diversify and evade human immunity. This evasion stems from amino acid substitutions, particularly in the receptor binding domain (RBD) of the spike protein that confers resistance to vaccine-induced antibodies and antibody therapeutics. To constrain viral escape through resistance mutations, we combined antibody variable regions that recognize different RBD sites into multispecific antibodies. Here, we describe multispecific antibodies, including a trivalent trispecific antibody that potently neutralized diverse SARS-CoV-2 variants and prevented virus escape more effectively than single antibodies or mixtures of the parental antibodies. Despite being generated before the appearance of Omicron, this trispecific antibody neutralized all major Omicron variants through BA.4/BA.5 at nanomolar concentrations. Negative stain electron microscopy suggested that synergistic neutralization was achieved by engaging different epitopes in specific orientations that facilitated binding across more than one spike protein. Moreover, a tetravalent trispecific antibody containing the same variable regions as the trivalent trispecific antibody also protected Syrian hamsters against Omicron variants BA.1, BA.2, and BA.5 challenge, each of which uses different amino acid substitutions to mediate escape from therapeutic antibodies. These results demonstrated that multispecific antibodies have the potential to provide broad SARS-CoV-2 coverage, decrease the likelihood of escape, simplify treatment, and provide a strategy for antibody therapies that could help eliminate pandemic spread for this and other pathogens.